Back to Search
Start Over
Kura Oncology, Mirati Therapeutics ink clinical collaboration & supply agreement to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC
- Source :
- PharmaBiz. November 4, 2023
- Publication Year :
- 2023
-
Abstract
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc., a commercial-stage targeted oncology company, announced [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.771500459